Integrated Cancer Repository for Cancer Research (iCaRe2)

University of Nebraska

Status: Enrolling

Conditions: Testicular Cancer; Ureter Cancer; Colon Cancer; Liver Cancer; Healthy Control; Bladder Cancer; Oral Cavity Cancer; Skin Cancer; Lip Cancer; Nasal Cavity Cancer; Duodenal Cancer; Breast Cancer; Penile Cancer; Lung Cancer; Ovarian Cancer; Leukemia; Urethral Cancer; Thymus Cancer; Oropharyngeal Cancer; Nasopharyngeal Cancer; Familial Adenomatous Polyposis; Multiple Myeloma; Gastric Cancer; Unknown Primary Tumor; Prostate Cancer; Anal Cancer; Plasma Cell Dyscrasia; Laryngeal Cancer; Melanoma; Esophageal Cancer; Central Nervous System Tumor; Vaginal Cancer; Small Intestine Cancer; Endometrial Cancer; Sarcoma; Lynch Syndrome; Thyroid Cancer; Pancreatic Cancer; Salivary Gland Cancer; Neuroendocrine Tumors; Hypopharyngeal Cancer; Peritoneal Surface Malignancies; Gallbladder Cancer; Gastrointestinal Stromal Tumors; Bile Duct Cancer; Paranasal Sinus Cancer; Kidney Cancer; Mesothelioma; Central Nervous System Cancer; Rectal Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT02012699

0253-13-EP

Details and patient eligibility

About

The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Full description

The integrated Cancer Repository for Cancer Research (iCaRe2 http://icare2project.org) is a unique sociotechnical resource for the collection and management of cancer and health-related data at the Fred & Pamela Buffett Cancer Center at University of Nebraska Medical Center (UNMC). The iCaRe2 is a multi-center, semantically-interoperable and easily-customizable cancer data resource which is aimed at collecting, managing, mining and sharing the comprehensive, multi-dimensional cancer-related data on cancer patients and biospecimens (such as tumor specimens, germ line DNA, serum, urine, and plasma) collected from those individuals.

The iCaRe2 provides: (i) a HIPAA compliant, secure, efficient and user-friendly mechanism for data and validation; (ii) utilization of standard vocabulary and data elements; and (iii) the ad-hoc data reporting capabilities. The iCaRe2 serves as a collaboration platform for studies (including clinical trials) performed in centers with expertise in cancer biology, pathology, epidemiology, genetics, early detection, and patient care.

The iCaRe2 has been developed as an expansion of the biocomputing framework that initially included four multi-center collaborative registries:

(i) the Pancreatic Cancer Collaborative Registry (PCCR) established in 2001, (ii) the Breast Cancer Collaborative Registry (BCCR) established in 2006, (iii) the Thyroid Cancer Collaborative Registry (TCCR) established in 2006, and (iv) the Great Plains Health Informatics Database (GPHID) established in 2011, to enroll subjects who have no personal history of cancer diagnosis at the time of enrollment.

At present, this framework has been incrementally expanded to include the Thoracic Oncology Collaborative Registry (TOCR), GenitoUrinary Cancer Collaborative Registry (GUCARE), Head and Neck Cancer Collaborative Registry (HNCCR), Gastrointestinal & Abdominal Cavity Cancer Collaborative Registry (GACCaRe), Central Nervous System Tumor Collaborative Registry (CTCR), Leukemia and Myeloid Neoplasm Registry (LEMN) , Gynecological Cancer Collaborative Registry (GCCR), Sarcoma Collaborative Registry (SARCR), Melanoma Collaborative Registry (MELCR), Plasma Cell Dyscrasias Collaborative Registry (PDCR), Neuroendocrine Collaborative Registry (NETR), and Auxiliary Cancer Registry (ACR).

The iCaRe2 group elected to use a "confederation model", as opposed to a traditional registry or network model. It was felt that these latter models implied that the registry or network would assume control of an individual Center's database. The major advantages of a confederation model include the flexibility to use selected Centers for different research projects based on a Center's resources and expertise and the ability to have different strategies to address various research questions. It was also recognized that for this model to be successful, it is essential to have a standardized approach to data collection (patient information and biospecimen annotation) and reporting. A confederation would also encourage participation of any interested Center, irrespective of its size or location. A web-based registry iCaRe2 was developed and made available to any Center to participate in data collection and storage of cancer related data.

Enrollment: 999,999 estimated patients

Sex: All

Ages: 19 to 110 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria.

• Adult individuals (male and female) who have a personal diagnosis/history of cancer
• Adult individuals who have a risk for developing cancer or suspicious clinical findings
• Adult individuals with no history of cancer for normal control registry.
• Able to provide consent.
• 19 years of age or older.
• Adult individuals who are able to speak English.

Exclusion Criteria.

• Individuals under age 19.
• Individuals unable to provide informed consent by virtue of cognitive impairment.
• Anyone who does not meet the above inclusion criteria for this project.
• Non-English speaking individuals.